SCOPUS 정보 검색 플랫폼

Pharmacy and Pharmacology Communications

Volumn 6, Issue 11, 2000, Pages 491-494

Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions

(4) Singh, S a Mariappan, T T a Sharda, N a Singh, B a

a Department of Pharmaceutics (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BIOEQUIVALENCE; DECOMPOSITION; DRUG DEGRADATION; DRUG FORMULATION; DRUG MARKETING; DRUG MIXTURE; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; STOMACH JUICE;

EID: 0033659569 PISSN: 14608081 EISSN: None Source Type: Journal
DOI: 10.1211/146080800128735575 Document Type: Article

Times cited : (53)

References (12)

1
- 0032711267
- Availability of quality fixed dose combinations for the treatment of tuberculosis: What can we learn from studying the World Health Organization's vaccine model?
- (1999) Int. J. Tuberc. Lung Dis. , vol.3
- Blomberg, B.¹ Kitler, M.E.² Milstien, J.³ Dellepiane, N.⁴ Fanning, A.⁵ Norval, P.Y.⁶ Spinaci, S.⁷

2
- 0020557426
- Bioavailability of rifampicin capsules
- (1983) Int. J. Clin. Pharmacol. Ther. Toxicol. , vol.21 , pp. 404-409
- Buniva, G.¹ Pagani, V.² Carozzi, A.³

3
- 0024364436
- Rifampicin raw material characteristics and their effect on bioavailability
- (1989) Bull. Int. Union Tuberc. Lung Dis. , vol.64 , pp. 36-37
- Cavenaghi, R.¹

4
- 0032737204
- Rifampicin bioavailability: A review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption
- (1999) Int. J. Tuberc. Lung Dis. , vol.3
- Ellard, G.A.¹ Fourie, P.B.²

5
- 0003985341
- WHO/CDS/TB/99/274, World Health Organization, Geneva
- (1999) Establislung the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to the single drug reference preparations administered in loose combination: model protocol
- Fourie, B.¹ Pillai, G.² McIlleron, H.³ Smith, P.⁴ Panchagnula, R.⁵ Ellard, G.⁶ Spinaci, S.⁷ Blomberg, B.⁸

6
- 0033860133
- A validated reverse-phase (C18) HPLC method for simultaneous determination of rifampicin, isoniazid and pyrazinamide in USP dissolution medium and simulated gastric fluid
- (2000) Pharm. Pharmacol. Commun. , vol.6 , pp. 345-349
- Mariappan, T.T.¹ Singh, B.² Singh, S.³

7
- 0033426974
- Bioequivalence study of rifampicin in fixed dose combination of rifampicin and isoniazid vs. separate formulations
- (1999) Methods Find. Exp. Clin. Pharmacol. , vol.21 , pp. 625-628
- Panchagnula, R.¹ Singh, I.² Kaur, K.J.³ Kaul, C.L.⁴

8
- 0032737205
- Recent bioequivalence studies on fixed dose combination antituberculosis drug formulations available on the global market
- (1999) Int. J. Tuberc. Lung Dis. , vol.3
- Pillai, G.¹ Fourie, P.B.² Padayatchi, N.³ Onyebujoh, P.C.⁴ McIlleron, H.⁵ Smith, P.J.⁶ Gabriels, G.⁷

9
- 0032859586
- Stability of rifampicin in dissolution medium in the presence of isoniazid
- (1999) Int. J. Pharm. , vol.190 , pp. 109-123
- Shishoo, C.J.¹ Shah, S.A.² Rathod, I.S.³ Savale, S.S.⁴ Kotecha, J.S.⁵ Shah, P.B.⁶

10
- 0033806376
- The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acidic conditions
- (2000) Pharm. Pharmacol. Commun. , vol.6 , pp. 405-410
- Singh, S.¹ Mariappan, T.T.² Sharda, N.³ Kumar, S.⁴ Chakraborti, A.K.⁵

11
- 85037796783
- 23/NF 18, United States Pharmacopeial Convention, Inc., Rockville, MD
- (1995) , pp. 2053

12
- 0032239849
- Results of examination in healthy volunteers of rifampicin and isoniazid bioavailability from polish-two drug combination capsules of rifamazid used for tuberculosis treatment
- (1998) Pneumonol. Alergol. Pol. , vol.66 , pp. 198-206
- Zofia, Z.¹ Niemirowska-Mikulska, H.² Augustynowicz-Kopec, E.³ Stambrowska, A.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.